Type 2 diabetes (T2D) is a chronic metabolic disorder characterised by high blood sugar and insulin insensitivity which greatly increases the risk of developing neurological diseases (NDs). The co-existence of T2D and comorbidities such as NDs can complicate or even cause the failure of standard treatments for those diseases. Comorbidities can be both causally linked and influence each other's development through genetic, molecular, environmental or lifestyle-based risk factors that they share. For T2D and NDs, such underlying common molecular mechanisms remain elusive but large amounts of molecular data accumulated on these diseases enable analytical approaches to identify their interconnected pathways. Here, we propose a framework to explore possible comorbidity interactions between a pair of diseases using a bioinformatic examination of the cellular pathways involved and explore this framework for T2D and NDs with analyses of a large number of publicly available gene expression datasets from tissues affected by these diseases. We designed a bioinformatics pipeline to analyse, utilize and combine gene expression, Gene Ontology (GO) and molecular pathway data by incorporating Gene Set Enrichment Analysis and Semantic Similarity. Our bioinformatics methodology was implemented in R, available at https://github.com/HabibUCAS/T2D_Comorbidity. We identified genes with altered expression shared by T2D and NDs as well as GOs and molecular pathways these diseases share. We also computed the proximity between T2D and neurological pathologies using these genes and GO term semantic similarity. Thus, our method has generated new insights into disease mechanisms important for both T2D and NDs that may mediate their interaction. Our bioinformatics pipeline could be applied to other co-morbidities to identify possible interactions and causal relationships between them.
I. INTRODUCTION
Type 2 diabetes (T2D) is a complex, chronic disorder whose causation is correspondingly multifactorial and heterogeneous. Many people developing T2D go through a stage of obesity-associated insulin resistance prior to the development of frank hyperglycemia [1] . The pancreatic islets respond to The associate editor coordinating the review of this manuscript and approving it for publication was Vincenzo Conti . insulin resistance by increasing their cell mass and insulin secretion but if this fails to compensate, chronic high levels of blood sugar (i.e., frank T2D) persists. High blood sugar levels result in glycation products that cause vascular inflammation and blockages, resulting in long-term complications and organ damage [1] , [3] , [24] . There are a number of hypothesized mechanisms (that are not mutually exclusive) to explain how insulin resistance and islet beta-cell dysfunction and T2D occurs and how it affects tissues. Glucotoxicity due to hyperglycaemia may impair insulin secretion [4] , [5] and cause beta-cell death or dysfunction [6] - [8] . Lipotoxicity due to increased serum triglycerides may impair β-cell secretory function [9] , [10] or cause apoptosis [11] , [12] . Oxidative stress may lead to the generation of reactive oxygen species to which beta cells are particularly vulnerable [13] - [15] . Endoplasmic reticulum (ER) stress may result from high insulin production causing the elevated beta-cell flux of proteins through the ER [16] - [18] , and this may drive insulin resistance [19] . Amyloid deposition in islets may also occur which can also reduce insulin sensitivity [20] . The relative contribution of these mechanisms is often unclear, but it is evident that a range of cell pathways involving many genes are involved in T2D development.
Genetic research has identified some genes associated with the risk of developing T2D. Genetic linkage based studies have identified two genes of particular importance, namely CAPN10 and TCF7L2. Candidate gene-based studies revealed numerous other genes that include PPARG, IRS1, IRS-2, KCNJ11, WFS1, HNF1A, HNF1B, HNF4A, RAPGEF1 and TP53. Moreover, genome-wide association studies show 38 genes associated with T2D [21] . One study identified ten loci (MTNR1B, SLC30A8, THADA, TCF7L2, KCNQ1, CAMK1D, CDKAL1, IGF2BP2, HNF1B, and CENTD2) to be associated with reduced beta-cell function, and three loci (PPARG, FTO and KLF14) associated with reduced insulin sensitivity [22] .
Thus, the intrinsic multifactorial nature of T2D marks it a very complex disease to understand and treat effectively [3] , [23] - [27] . However, an important clinical issue is that there are many diseases that commonly occur in association with T2D, notably NDs [28] - [36] ; as comorbidities of T2D, ND development may be caused or exacerbated by the activation of molecular pathways and disease-causing genes they share with T2D. This includes pathways and genes involved in inflammation and response to high glycation products or those involved in responses to glucose and lipid toxicity, oxidative and ER stress and amyloid deposition. The co-existence of two or more such serious diseases can greatly complicate treatments for individual diseases and, indeed, greatly elevate mortality [37] .
As much multi-omics data has been released into the public domain, analysing such data to identify common pathways shared by different diseases that can occur as comorbidities have become an important use of bioinformatics. Nevertheless, the available data and information are usually deliberated in isolation and rarely combined due to the lack of an appropriate bioinformatics approach. This lack of combination studies results in overlooking important disease-causing factors that act synergistically to cause the complex comorbidity. The integration of different bioinformatics tools can provide methodologies that extract more discriminating information from the available data on disease interactions.
As T2D results in an increased risk of NDs, it is likely that these have shared molecular factors that enable their interaction in the same individual. Since these underlying common molecular mechanisms remain elusive, in this study we designed and implemented a bioinformatic pipeline to utilize and combine gene expression, gene ontology (GO) and molecular pathway data by incorporating Gene Set Enrichment Analysis and Semantic Similarity studies. In addition, we have incorporated semantic similarity approaches to use genes and GO terms to measure the proximity of the comorbidities to identify biological processes important to each disease. Moreover, we performed the verification of the results with gold benchmark databases and literature.
II. METHODOLOGY A. SURVEY OF AVAILABLE DATA
We retrieved gene expression microarray data for this study from the public repository available at National Center for Biotechnology Information (NCBI) (http:// www.ncbi.nlm.nih.gov/geo/) [38] . Queries for T2D initially returned 1547 datasets from which most of the datasets were discarded considering the following issues and finally selected datasets with a minimum number of 6 samples to exploit the maximum power of the study. We have employed the following criteria for selecting the datasets for our study: 1) Studies in which samples from an earlier study were re-analysed or investigated with the different processes were not considered for our study. 2) Some datasets are related to T2D or NDs, but samples used were of a type (e.g., type of cell extract) irrelevant for our study were not considered. 3) Only data from human subjects were used. 4) We considered only those datasets whose differentially expressed genes (DEGs) count is greater than 50 when applying a threshold value of absolute 1 for log fold change (logFC).
Gene expression datasets for T2D disease yielded the following datasets from GEO repositories: GSE20966, a study of 10 control and 10 T2D subjects from pancreatic tissue [39] ; GSE23343, a study of 7 control subject and 10 T2D subjects using liver biopsies [40] ; GSE25724, a study of 7 control and 6 T2D subjects using pancreatic islet tissue [41] ; GSE29221, an analysis of 3 control and 3 T2D subjects using skeletal muscle cell samples [42] ; GSE29226, a study of 3 control and 3 T2D subjects using subcutaneous tissue samples [43] ; GSE29231, a study of 3 control and 3 T2D subjects using visceral adipose tissue [44] ; and GSE55650, a study of control and T2D subjects from muscle cell samples. It should be noted that for the last dataset, the data was divided into two parts based on extraction and separate analysis of myoblasts and myotubes; for myoblasts, there were 6 control and 6 T2D subjects and for myotubes, 5 control and 6 T2D [45] .
For the comorbidity interactions analysis, our selected studies on neurological diseases used the following datasets. For Alzheimer Disease (AD) we used dataset GSE1297, a study of 9 control and 22 AD subjects using hippocampal CA1 tissue [46] ; GSE4226 and GSE4229, which included studies of peripheral blood cells using normal elderly control (NEC) and AD subjects [47] , [48] ; GSE12685, a study of 8 control and 6 AD subjects using frontal cortex synaptoneurosome samples [49] ; and GSE28146, a study of 8 control and 22 AD subjects using laser captured CA1 tissue [50] . To study Parkinson's Disease (PD) we used dataset GSE7621, a study of 9 control and 16 PD subjects from substantia nigra tissue from both male and female subjects [51] ; GSE19587, a study of 5 control and 6 PD subjects using post-mortem brain tissue samples [52] ; GSE20141, an analysis of 8 control and 10 PD subjects also using the post-mortem brain tissue samples [53] ; GSE20333, an analysis of 6 control and 6 PD subjects using substantia nigra tissue samples; GSE22491, an analysis of 8 control and 10 PD subjects using peripheral blood samples [54] ; GSE28894, a study of tissue samples from four different brain regions with control and PD subjects; GSE42966, analysis of 6 control and 9 PD subjects using substantia nigra tissue samples; and GSE54536, a study of 5 control and 5 PD subjects using peripheral blood samples [55] , [56] . For the case of Amyotrophic Lateral Sclerosis (ALS) we used dataset GSE833, a study of 4 control and 7 sporadic and familial ALS subjects using post mortem spinal cord [57] ; GSE4595, an analysis of 9 control and 11 sporadic ALS subjects using human motor cortex tissue samples [58] ; GSE19332, a study of 7 control and 3 sporadic ALS subjects using motor neuron tissue samples [59] ; GSE52672, an analysis of 10 control and 10 sporadic ALS and familial ALS subjects using whole spinal cord homogenate [60] ; and GSE68605, a study of 3 control and 8 ALS subjects using motor neuron tissue samples [61] . To study Epileptic Diseases (ED) we used dataset GSE22779, a study of 4 control and 12 ED subjects using mononuclear blood cells [62] ; and GSE32534, a study of 5 control and 5 ED subjects using peritumoral neocortex tissue samples [63] . To study Huntington's Disease (HD) we used dataset GSE1751, a study of 14 control and 17 HD subjects using human blood samples [64] ; GSE1767, a study of 14 control and 17 HD subjects using lymphocyte cells extracted from blood samples [65] ; GSE24250, a study of whole blood samples using 6 control and 8 HD subjects [66] ; and GSE77558, an analysis of 6 control and 6 HD subjects from striatum-like tissue samples [67] . To study Cerebral Palsy (CP) we used dataset GSE11686, a study of 4 control and 12 CP subjects using muscle biopsies [68] ; and GSE31243, a study of 20 control and 20 CP subjects using skeletal muscle biopsies [69] . To study Multiple Sclerosis (MS) we used dataset GSE7102, a study of 6 control and 6 treated MS subjects; GSE16461, a study of 8 control and 8 MS subjects using CD4+ T cells from blood samples [70] ; GSE17048, a study of 54 control and 99 MS subjects using peripheral blood cell samples [71] ; GSE21942, a study of 15 control and 12 MS subjects using peripheral blood samples [72] ; GSE26484, a study of 4 control and 3 MS subjects using peripheral blood samples [73] ; GSE32915, a study of 4 control and 12 MS subjects using brain tissue [74] ; GSE37750, a study of 8 control, 9 before treatment and 9 after treatment subjects using extracted plasmacytoid dendritic cells (pDC) [75] ; GSE52139, a study of 8 control and 8 MS subjects using spinal cord samples [76] ; and GSE103005, a study of 12 control and 8 MS subjects using whole blood samples.
B. GENE SET ENRICHMENT ANALYSIS
Gene set enrichment analysis (GSEA) is an analytical method based on statistical approaches that interpret gene expression data to identify a set of DEGs with altered expression levels [77] . These genes may be interconnected with disease phenotypes. GSEA uses a set of previously grouped genes having common biological pathway involvement or chromosomal location. It compares genes obtained from two cell categories through DNA microarray or next-generation sequencing (NGS) by analysing their expression levels in different conditions or disease states. The gene set that falls in the extremes of this list: up-regulated and down-regulated are considered to be associated with the phenotypic differences.
1) PATHWAYS
Molecular pathway comprised of a series of actions within the molecules of the human cells that cause a certain product or change in the cell. This kind of pathway triggers the assembly of new molecules. Moreover, a pathway can also turn genes on or off. To make insights into the molecular pathways of T2D that overlap with NDs, we employed KEGG databases [78] to identify molecular pathways enriched by the DEGs.
2) ONTOLOGIES
Gene ontology (GO) is a conceptual model of gene product functions that can give important information about those systems or pathways that are significantly involved in a disease or biological function. GO datasets represent an ongoing project aims to give and ever-more comprehensive and updated structured information about biological systems [79] . GO has three domains: cellular component, molecular functions and biological process (BP). We focused on BP in this study.
3) SEMANTIC SIMILARITY
To measure the proximity of the genes and GO terms, we incorporated the semantic similarity. Semantic similarity is a method to measure proximity using ontologies to estimate the closeness between terms/concepts by defining a topological similarity [80] . This is a graph-based approach using directed acyclic graphs (DAGs) of terms (genes, GO). The semantics of these terms depends on its position in the DAG and its semantic contribution factor with all of its ancestor terms.
Formally, a GO term P can be represented as a graph DAG P = (P, T P , E P ), where T P is the set of all GO terms in DAG P as ancestor terms of P together with term P itself in the GO graph and E P is the set of corresponding edges that connect the GO terms in DAG P . The semantic value of GO term P is numerically calculated as,
where w e is the semantic contribution multiplier for edge e (e ∈ T P ), generic term t with its child term t . The semantic contribution is assigned between 0 and 1 according to the type of association. The global semantic value for P is calculated as
Now, if DAG P = (P, T P , E P ) and DAG Q = (Q, T Q , E Q ) are two terms P and Q respectively then the semantic similarity between P and Q is
Given two sets of terms P 1 = t 11,t 12 ,...t 1k and Q 1 = t 21,t 22 ,...t 2n , where the first set of terms length is k and the second set of terms length is n. To calculate the semantic similarity, we applied the best-match average (BMA) [81] for two given sets as follows:
with i, j indices on P, Q terms. Figure 1 shows the steps of the pipeline of the proposed methodology:
C. THE PIPELINE OF THE PROPOSED METHODOLOGY
• DATA RETRIEVAL. At first, we downloaded the selected GEO datasets along with their associated platform and phenotype information and transformed this into an expression set class object. We considered disease affected patients and healthy controls for T2D for identifying DEGs;
• MODEL DESIGN. We reviewed the GSM records manually, classified samples and created design models. The design model was T2D vs control for T2D and ND vs control or ND vs treated for the NDs were the designed model;
• LINEAR and BAYESIAN MODEL for DIFFER-ENTIAL EXPRESSION. A linear and a bayesian method [82] are applied for filtering the design model using three parameters p-value, adjusted p-value (False Discovery Rate) and logFC. Using a threshold of at most 0.05 and at least 1.0 absolute value for p-value and logFC respectively, differentially expressed genes are identified;
• GO TERMS TEST. In this stage, we build the class top-GOdata by using selected significant genes and stipulating the GO domain along with specifying the annotation for mapping. To obtain filtered GO terms and their relationships with genes, we employed Fisher's exact test [83] .
• SEMANTIC SIMILARITY. After carried out the mapping, we performed the semantic similarity comparisons by means of genes and GO terms to measure the proximity among all selected T2D and ND datasets;
• CLUSTER COMPARISON. In this stage, we also carry out a KEGG pathway [78] enrichment test for the differentially expressed genes to identify a significant molecular pathway for T2D and its neurological comorbidities;
• RESULTS. The output of the pipeline of bioinformatics methodology consists of statistical summary, correspondences of genes-GO terms, DAG, gene semantic similarity matrix (and dendrogram), GO semantic similarity matrix (and dendrogram), and KEGG enrichment pathways/pathologies list. In addition, we have constructed a gene network using significant DEGs that are common to T2D and NDs along with the most prevalent pathway related to the selected pathologies.
The proposed integrated pipeline of the bioinformatics methodology is implemented in R language available at the link: https://github.com/HabibUCAS/T2D_Comorbidity. Following Bioconductor packages [84] , we developed the proposed methodology using GEOquery [85] for downloading GEO datasets and expression set class transformation;
limma [82] for differentially expressed gene identification from microarray data; genefilter [86] for filtering genes; topGO [83] for building the topology of DAG and identifying the significant GO terms; GOSemSim [87] for measuring the proximity among selected pathologies; clusterProfiler [88] for the KEGG pathways enrichment analysis. Eventually, the version of the used software and packages are: R 3. 
III. RESULTS

A. STATISTICS AND GENE COMPARISON
Since each dataset has two/three conditions such as control vs case or control vs treated and after performing the statistical test for these conditions applying limma [82] , we get differentially expressed genes. The statistical summary for all the selected T2D studies is tabulated in Table 1 . Table 2 summarizes common neurological disease comorbidities for T2D. The dataset legend: Alzheimer's Disease (AD): GSE1297, GSE4226, GSE4229, GSE12685, GSE28146; Amyotrophic Lateral Sclerosis (ALS): GSE833, GSE4595, GSE19332, GSE52672, GSE68605; Cerebral Palsy (CP): GSE11686, GSE31243; Epilepsy Disease (ED): GSE22779, GSE32534; Huntington Disease (HD): GSE1751, GSE1767, GSE24250, GSE77558; Multiple Sclerosis (MS): GSE7102, GSE16461, GSE17048, GSE21942, GSE26484, GSE32915, GSE37750a, GSE37750b, GSE52139, GSE103005; Parkinson Disease (PD): GSE7621, GSE20141, GSE20333, GSE22491, GSE42966, GSE19587, GSE28894 and GSE54536.
In Table 1 and Table 2 , P-values are the results of applying a statistical test that takes into account the mean difference and the variance and also the sample size. So, choosing a cut off of 0.05 means there is a 5% chance that we make the wrong decision. It implies that 5% of the tests found to be statistically significant that is false positives is accepted in this study. The sixth column values of Table 1 and Table 2 indicate the number of differentially expressed genes with the cut-off p-value of 0.05. In the GSEA, the number of statistically significant genes based on the cut-off p-value of 0.05 is found with up and down-regulated expression levels. Log2 fold change (logFC) is the log-ratio of a gene's expression levels in two different conditions such as control vs case or control vs treated and it is used to measure the changes in expression level. In the seventh column of Table 1 and Table 2 , we tabulated the number of differentially expressed genes with the cut-off logFC value of 1. For GO enrichment analysis, finding raw GSEA is the first stage of the GO enrichment analysis. In this stage, we performed gene to gene ontology mapping using differentially expressed genes from the biological process (BP) domain of the gene ontology. The eight column values in Table 1 and Table 2 indicates the number of annotated gene ontology (GO) terms from the differentially expressed genes. After mapping the gene to GO terms, we applied 'Fisher's exact test' [83] statistics to get statistically significant GO terms. Fisher's exact test is based on gene counts. We performed a classical enrichment analysis with Fisher's exact test by testing the over-representation of GO terms within the group of differentially expressed genes. The ninth column is the Fisher GSEA and its values in Table 1 and Table 2 indicate the number of significant GO terms enriched from the Fisher exact test. Table 3 narrates the summarised results of all the datasets along with the number of analysed DEGs considering the top 50 genes for each dataset.
After identifying top the 50 DEGs for all datasets, we compared the T2D and each ND. The comparison of the differential expressed genes between the T2D data sets and the neurological diseases shows that the following genes are held in common: RIN3, CR1, SORL1, MEF2C, HS3ST1, RGS4, HLA-DRB4, STMN2, F2RL1, BGN, PON2, APOE, HFE, ITPR2, SERPINA3, PTEN, SER-PINB6, PCSK1, PNMA2, RTN1, NEFL, XCL11, PKP1, TENM1, CCL2, CHL1, GNAS, GREM1, MYH1, IGFBP5, TNC, GATA6, AKT3, UBE3A, GATM, SYN1, CNT-NAP2, LYZ, COL6A3, MGP, UCHL1, MATR3, C9orf72, TRPM7, CHMP2B, SS18L1, TBK1, SLC25A36, HLA-DRB1, CD24, IL2RA, HLA-DQB1, IL4, CSMD1, RAB3IP, MAFB, HLA-DRB5, S100A12, NFIB, CXCL8, IFI44L, EBF2, PLA2G6, VPS13C, ATP6AP2, SCARB2, TMEM163, DGKQ, MAOA, SREBF1, SYT11, RIT2, GSTZ1, SNCA, BST1. A cluster network with this list of common genes is constructed using the online tool GeneMania [89] considering co-expression, consolidated pathways, co-localization, shared protein domain, predicted and physical interaction as shown in Figure 2 . second messenger molecules (0.86%), alpha-synuclein signaling (0.65%), downstream TCR signaling (0.62%), graftversus-host disease (0.61%).
B. PATHWAY ENRICHMENT
The pathway-based analysis is a recently developed approach to understand how complex diseases may be related to each other through their underlying molecular mechanisms. After identifying DEGs, we performed KEGG pathway enrichment analysis. The relationships between KEGG pathways and all the selected datasets are represented in Figure 3 . Resulting pathways in common between T2D and neurological pathologies with at least two evidence include: Influenza A, NOD-like receptor signaling pathway, Cytokine-cytokine receptor interaction, Chagas disease (American trypanosomiasis), Toll-like receptor signaling pathway, Human cytomegalovirus infection, Malaria, Autoimmune thyroid disease, Tuberculosis, PI3K-Akt signaling pathway, Melanoma, Human papillomavirus infection, Neuroactive ligand-receptor interaction, Epstein-Barr virus infection, Taste transduction, Focal adhesion, ECM-receptor interaction, Protein digestion and absorption, Relaxin signaling pathway, EGFR tyrosine kinase inhibitor resistance, cAMP signaling pathway and Amoebiasis.
C. GO ENRICHMENT AND GO TERMS TREE
The suggested biological process involved in each dataset using DEGs on type 2 diabetes disease is as follows:
• GSE20966: humoral immune response, humoral immune response mediated by circulating immunoglobin, regulation of complement activation, complement activation, cellular response to zinc ion, neuron projection extension involved in neuron projection guidance and central nervous system neuron development;
• GSE23343: myofibril assembly, cell communication by electrical coupling, astrocyte development, chemokine secretion, cell aggregation, and G protein-coupled receptor internalization;
• GSE25724: regulation of the cellular amino acid metabolic process, posttranscriptional regulation of gene expression, anaphase-promoting complex-dependent catabolic process, regulation of mRNA catabolic process and cellular protein catabolic process;
• GSE29221: extracellular structure organization, extracellular matrix organization, blood circulation, collagen fibril organization, muscle system process and G protein-coupled receptor signaling pathway;
• GSE29226: sensory perception of chemical stimulus, neurological system process involved in the regulation of systemic arterial blood pressure, regulation of T-helper 2 cell cytokine production, nervous system process, and complement activation, lectin pathway;
• GSE29231: trophoblast giant cell differentiation, regulation of metanephros development, developmental induction, ERBB2 signaling pathway, regulation of ERBB signaling pathway and cell proliferation;
• GSE55650a: regulation of cell migration, nuclear division, regulation of cell motility, cell migration, cell motility, and biological adhesion;
• GSE55650b: circulatory system development, extracellular matrix organization, striated muscle cell differentiation, extracellular structure organization, anatomical structure morphogenesis and cellular response to type I interferon. Direct Acyclic Graphs (DAG) for each selected pathology were constructed using a classic algorithm [83] . Figure 4 shows how the significant GO terms are distributed over the GO graph hierarchy with the 5 most significant GO terms (GO: 007087: cellular response to chemical stimulus, GO: 0010033: response to organic substance, GO: 0071310: cellular response to organic substance, GO: 0009653: anatomical structure morphogenesis and GO: 0071294: cellular response to zinc ion). Since the test statistic can return a p-value, we can refer them as criteria to select statistically significant GO terms. After mapping genes to GO terms, we applied Fisher's exact test statistics and classic algorithms to deal with GO enrichment analysis and GO graph structure. Fisher's exact test was applied to gene count. We identified the most significant GO terms (top 5) based on p-values by classical enrichment analysis. The DAG graph reveals that all the GO terms are non-trivial and the most significant nodes are represented as rectangles. For each node in the graph, the first line is GO ID, the second line is GO name, third is p-value and the last line is the ratio of the total number of significant genes and the total number of annotated genes to the respective GO term. Black arrows indicate is-a relationships.
However, after identifying the significant GO terms for T2D and NDs, we compared the terms. The GO terms comparison between T2D disease and NDs highlights the following in common:
• GO:0001502: cartilage condensation; • GO:0098743: cell aggregation; • GO:0006959: humoral immune response; • GO:0002455: humoral immune response mediated by circulating immunoglobulin;
• GO:0006958: complement activation, classical pathway;
• GO:0007186: G protein-coupled receptor signaling pathway;
• GO:0043062: extracellular structure organization; • GO:0030198: extracellular matrix organization; • GO:0030199: collagen fibril organization; • GO:0016477: cell migration; • GO:0048870: cell motility;
• GO:0002673: regulation of acute inflammatory response; item GO:0030199: collagen fibril organization;
• GO:0007059: chromosome segregation; • GO:0022610: biological adhesion; • GO:0071294: cellular response to zinc ion; • GO:0007632: visual behavior; • GO:0035459: cargo loading into vesicle; • GO:0038128: ERBB2 signaling pathway; • GO:0009653: anatomical structure morphogenesis; • GO:1902284: neuron projection extension involved in neuron projection guidance;
• GO:0007416: synapse assembly; • GO:0048483: autonomic nervous system development;
• GO:0060337: type I interferon signaling pathway; • GO:0071357: cellular response to type I interferon;
• GO:1903522: regulation of blood circulation; • GO:0050906: detection of stimulus involved in sensory perception;
• GO:0050877: nervous system process;
• GO:0007600: sensory perception;
• GO:0010469: regulation of signaling receptor activity.
D. SEMANTIC SIMILARITY
The result of semantic similarity in terms of DEGs among pathologies is shown in Figure 5 . Considering semantic similarity value above 0.6, T2D4_GSE29221 and VOLUME 7, 2019 FIGURE 6. The network for representing the gene semantic similarity matrix shown in figure 5 . The width of the edges is proportional to the semantic score and the red colour hexagonal node represents the T2D and the light blue colour rectangular node represents T2D associated NDs.
T2D5_GSE29226 are associated with all the selected neurological comorbidities except HD01_GSE1751 and HD04_GSE77558. Similarly, T2D1_GSE20966 is associated with all the selected neurological comorbidities except HD01_GSE1751 and ED01_GSE22779. T2D2_GSE23343 is associated with all the selected neurological comorbidities except HD04_GSE77558 whereas T2D8_GSE55650b is associated with all the selected neurological comorbidities except HD04_GSE77558. With respect to other evidence from T2D3_GSE25724, all neurological diseases are associated with T2D. In addition, AD02_GSE4226 and AD03_GSE4229 are outliers for all T2D datasets except T2D3_GSE25724 with a threshold value of absolute logFC 1. After representing the gene semantic similarity matrix as shown in figure 5 into gene semantic similarity network as shown in Figure 6 by considering the semantic similarity threshold value of 0.77 using Cytoscape [97] we found that T2D such as T2D1_GSE20966, T2D2_GSE23343, T2D3_GSE25724, T2D4_GSE29221, T2D5_GSE29226 T2D6_GSE29231, T2D7_GSE55650a T2D8_GSE55650b are strongly associated with all the NDs such as AD, ALS, CP, ED, HD, MS, and PD.
The semantic similarity matrix of GO terms is depicted in Figure 7 . Notably, T2D7_GSE55650a with AD03_ GSE4229, T2D5_GSE29226 with AD05_GSE28146 and MS02_GSE16461, T2D6_GSE29231 with MS10_GSE1030 05 as well as T2D7_GSE55650a with PD02_GSE19587 have semantic similarity value of 1. If we examine semantic similarity value over 0.8, some of AD, ALS, CP, ED, HD, MS, and PD have noteworthy similarity with some of the T2D datasets. Moreover, inspecting semantic similarity value over 0.7, T2D3_GSE25724 is well clustered with all the neurological diseases except MS08_GSE37750b and ALS4_GSE52672. In addition, MS08_GSE37750b, ED02_GSE32534, ALS5_GSE68605 and AD04_GSE12685 have semantic similarity under 0.05 for T2D5_GSE29226 and T2D1_GSE29231 whereas ALS5_GSE12685 has semantic similarity under 0.05 for T2D6_GSE29231.
After representing the GO semantic similarity matrix shown in figure 7 into gene semantic similarity network as shown in Figure 8 by considering the semantic similarity threshold value of 0.80 using Cytoscape [97] we found that T2D such as T2D1_GSE20966, T2D2_GSE23343, T2D3_GSE25724, T2D4_GSE29221, T2D5_GSE29226, T2D6_GSE29231, T2D7_GSE55650a T2D8_GSE55650b are strongly associated with all the selected NDs such as AD, ALS, CP, ED, HD, MS, and PD.
We applied this proposed bioinformatics methodology to identify T2D and its neurological comorbidities on microarray gene expression datasets. Identifying the interactions among a group of diseases at the molecular level can enhance our insights into disease mechanisms. The use of semantic similarity in terms of genes and GO terms to measure the disease comorbidity enhances the identification and characterization beyond simply identifying novel biological processes involved in each disease and eventually yields an opportunity for developing diagnosis and effective treatment. Most previous methods were designed for disease comorbidity study by considering either single omics or clinical dataset as for example comorbidity [90] , [91] , comoR [93] , POGO [94] , Comorbidity4j [95] , comoRbidity [96] and CytoCom [97] . The R package 'comorbidity' is able to predict ICD-9-CM codes on the basis of comorbidity indices. This method measures the total comorbidity count or the total Charlson score [90] , [91] . In [92] , Hidalgo et al. identified comorbidity association using clinical data. In [93] , the R package comoR measures relative risk and φ-correlation leveraging diagnosis, gene expression, and clinical data and identified related genes and pathways to predict comorbidity. This method considers only gene expression and molecular data. Moni et. al developed [94] an R software tool ''POGO'' to identify disease comorbidity by considering omics, phenotype, and ontological data but this method did not take into account the genetic effects on diseases. In [95] Compared to previous methods, most previously published methods in this area were designed to identify the causal relationship for disease comorbidities by considering either a single omics or clinical datasets. We have in contrast applied an integrated approach leveraging large numbers of publicly available gene expression datasets with pathway information, gene ontology data from microarray experiments which is a highly effective means of identifying pathways relevant to comorbidity interaction. The use of so many datasets from different sources and cell types maximizes the power of this approach by reducing biases of the datasets and improve the information regarding other previous studies. Our pipeline would thus be useful to reveal hidden pathological information in many different types of published gene expression datasets. As far we know, this is the first study for T2D and NDs comorbidity analysis by incorporating Gene Set Enrichment Analysis and Semantic Similarity and perhaps there are no previous comorbidity analysis methods for T2D and NDs incorporating Semantic Similarity. The methodology ensures the possibility of reusing available data and may identify disease-causing DEGs, gene function, GO terms and molecular pathways. The findings documented in this result section are likely to be improved by exploiting the maximum power of datasets from different sources and cell types. Thus, this methodology could be helpful to reveal new information from previously published datasets. VOLUME 7, 2019 FIGURE 8. The network for representing GO semantic similarity matrix shown in figure 7 . The width of the edges is proportional to the semantic score and the red colour hexagonal node represents the T2D and the light blue colour rectangular node represents T2D associated NDs.
E. POTENTIAL TARGETS VERIFICATION USING GOLD BENCHMARK DATABASES AND LITERATURE
To verify our identified potential targets, we used gold benchmark databases and an investigation of the literature. OMIM, OMIM Expanded, and dbGaP databases are called gold benchmark databases because these databases contain curated and validated genes and disease association data from the literature. In this study, we presented a combined relation of OMIM, OMIM Expanded, and dbGaP databases. For evaluating the validity of our work, we provided statistically significant differentially expressed genes of T2D to the online tool EnrichR [98] and collected statistically significant genes and their corresponding NDs from OMIM, OMIM Expanded, and dbGaP databases by choosing p-value of 0.05. The number of genes associated with each ND is educed and summarized in fewer genes with their molecular functions by checking the literature to find genes that have been clinically used as biomarkers for any of the NDs. Table 4 shows the verified potential targets and their corresponding diseases using gold benchmark databases and literature. For the verification of AD, ALS, MS, and PD, we utilized gold benchmark databases through online tool EnrichR and genes are curated in fewer genes by checking the literature. On the other hand, for the verification of CP, ED, and HD, we used literature which found genes associated with each ND. Munshi et al. [99] identified APP, SORL1 and CR1, Cauwenberghe et al. [101] , [102] identified MEF2C genes associated with AD which consistent with our study. Chen et al. [103] - [105] identified PON2, Eykens et. al [106] identified APOE and Souza et al. [107] , [108] identified ITPR2 and VAPB genes associated with ALS which consistent with our study. Fahey et al. [109] identified the TENM1 gene associated with CP and consistent with our study. Myers et al. [113] identified CHD2 and PURA genes associated with ED and consistent with our study. Arning and Epplen [114] reported the ITPR2 gene associated with HD. Baranzini [115] identified HLA-DQB1 and IL2RA genes, Fagerberg et al. [110] identified HMGA2 and Gabriele et. al identified CD24 gene associated with MS. Arning and Epplen [114] identified UCHL1, Fagerberg et. al reported TSHR, Myers et al. [113] identified SNCA and Lin et. al identified MAPT gene associated with PD which consistent with our study. This verification process generally confirms that significant genes that we have identified in NDs have some known disease associations.
The molecular basis of the verified potential targets are as follows: Amyloid precursor protein (APP) gene encodes a cell surface receptor and transmembrane protein that is cleaved by βand γ -secretase in a sequential manner to yield Aβ-peptides (including Aβ40 and Aβ42). The Aβ peptides are involved in the pathogenesis of AD [99] . SORL1 (Sortilin related receptor 1) also known as SORLA and LR11 is involved in regulating protein movements through the cell and identified as biomarkers for AD [99] . Complement C3b/C4b receptor 1 (CR1) gene mediates cellular binding to particles and immune complexes that have activated complement and associated with AD [99] , [100] . Myocyte enhancer factor 2C (MEF2C) plays a role in myogenesis. Mutations of this gene associated with immune response, neuronal development and synaptic function for developing AD [48] , [101] . Paraoxonase 2 (PON2) is involved in the hydrolysis of lactones and the detoxification of organophosphate pesticides, neurotoxins, and aromatic esters. The mutations of PON gene polymorphisms are associated with ALS [103] . Apolipoprotein E (apoE denotes protein, APOE denotes gene) is a lipid transport protein in the brain. The mutations APOE results in a major risk of ALS [106] . Inositol 1, 4, 5-trisphosphate receptor type 2 (ITPR2) is involved in many processes including cell migration, cell division, smooth muscle contraction, and neuronal signaling. A mutation in this gene has been associated with ALS and HD [107] . Vesicle-associated membrane protein-associated protein B (VAPB) is an integral endoplasmic reticulum membrane protein, which has various functions such as intracellular vesicle trafficking, lipid transport, and the unfolded protein response and associated with ALS [107] . Teneurin transmembrane protein 1(TENM1) functions as a cellular signal transducer. Its mutation involved in neural development, regulating the establishment of proper connectivity within the nervous system causes CP [109] . C-C Motif Chemokine Ligand 2 (CCL2) is superfamily of secreted proteins involved in immunoregulatory and inflammatory processes and associated with CP [110] . Cell adhesion molecule L1-like (CHL1) plays a role in neuronal positioning of pyramidal neurons and in the regulation of both the number of interneurons and the efficacy of GABAergic synapses and associated with CP [111] . Gremlin 1 (GREM1) plays a role in regulating organogenesis, body patterning, and tissue differentiation associated with CP [110] . GATM glycine amidinotransferase (GATM) is involved in creatine biosynthesis. Mutations in this gene cause arginine: glycine amidinotransferase deficiency, an inborn error of creatine synthesis characterized by cognitive disability, language impairment, and behavioral disorders associated with ED [112] . Ubiquitin protein ligase E3A (UBE3A) is maternally expressed in the brain and bi-allelically expressed in other tissues. Maternally inherited deletion of this gene causes Angelman syndrome, characterized by severe motor and intellectual retardation, ataxia, hypotonia, epilepsy, absence of speech, and characteristic facies [112] . CHD2 (Chromodomain Helicase DNA Binding Protein 2) is a protein-coding gene. Its function may be regulation of chromatin structure, and diseases associated with CHD2 include epileptic encephalopathy [113] . Purine rich element binding protein A(PURA) is involved in the formation or maturation of myelin, the protective substance that covers nerves and promotes the efficient transmission of nerve impulses and associated with ED [113] . Ubiquitin carboxy-terminal hydrolase L1 (UCHL1) is a de-ubiquitinating enzyme with important functions in the recycling of ubiquitin expressed in the neurons and cells of the diffuse neuroendocrine system and associated with HD [114] . The protein encoded by MATR3 (Matrin 3) gene is localized in the nuclear matrix plays a role in transcription or may interact with other nuclear matrix proteins to form the internal fibro granular network and is associated with HD [110] . C9orf72-SMCR8 complex subunit (C9orf72) gene provides instructions for making a protein that is abundant in nerve cells (neurons) in the outer layers of the brain (cerebral cortex) and in specialized neurons in the brain and spinal cord that control movement (motor neurons) and associated with HD [110] . HLA-DQB1 major histocompatibility complex, class II, DQ beta 1(HLA-DQB1) belongs to the HLA class II beta chain paralogs and plays a central role in the immune system by presenting peptides derived from extracellular proteins and associated with MS [115] . High mobility group AT-hook 2 (HMGA2) functions as a transcriptional regulator and associated with MS [110] . Interleukin 2 receptor subunit alpha (IL2RA) is involved in the regulation of immune tolerance by controlling regulatory T cells (TREGs) activity and associated with MS [115] . The protein encoded by signal transducer CD24 also known as cluster of differentiation 24 or heat-stable antigen CD24 (HSA) contributes to a wide range of downstream signaling networks and is crucial for neural development and associated with MS [116] , [117] . Ubiquitin carboxy-terminal hydrolase L1 (UCHL1) gene is a de-ubiquitinating enzyme with important functions in the recycling of ubiquitin and is specifically expressed in the neurons and in cells of the diffuse neuroendocrine system associated with PD [114] . Alpha-synuclein (SNCA) protein encoded by SNCA (Alpha-synuclein) is present at high levels in neurons and regulates dopamine neurotransmission, and its aberrant expression is associated with PD [118] . The protein encoded by the thyroid-stimulating hormone receptor (TSHR) gene is a membrane protein and a major controller of thyroid cell metabolism. Defects in this gene are also seen in PD [110] . Microtubule-associated protein tau (MAPT) encodes a microtubule-associated protein tau, which has a role in stabilizing microtubules in the neurons and its mutations are associated with PD [119] .
IV. DISCUSSION
The goal of this research is to establish the ability of an integrated pipeline of bioinformatics methodology to extract discriminative information from public data repositories and identifying the relationships of complex VOLUME 7, 2019 diseases such as T2D and its neurological comorbidities. We applied this proposed bioinformatics methodology to identify T2D and its neurological comorbidities on microarray data from Gene Expression Omnibus (GEO) repository: (https://www.ncbi.nlm.nih.gov/geo).
We employed GSEA to study T2D with regard to DEGs, molecular pathways, and interrelationship among omics data such as Gene Ontology. A particular feature of our proposed methodology is computing the proximity (in terms of semantic similarity) among different datasets based on their selected ontology. Although we applied our proposed integrated bioinformatics pipeline for T2D and its neurological disease comorbidities, it is methodically universal and can be applied for other diseases and their comorbidities along with more complex pathologies. Our proposed pipeline shows a novel use of freely available research data in exploring disease comorbidity from a bioinformatics point of view. The only manual task needed to be was that rather than the automatic selection of GEO samples, we reviewed the GSM records manually and classified samples into sick, healthy or treated and created design models.
At least 3 disease-affected and 3 healthy control samples were considered in our study for each disease case to exploit the maximum power of the study. We began from the set of DEGs and carried out GSEA on them to identify the top 5 GO terms. A comparison among all the selected pathologies in terms of genes and GO terms were computed by applying the method of semantic similarity. The use of semantic similarity in terms of genes and GO terms to measure the disease comorbidity enhances the identification and characterization beyond simply identifying novel biological processes involved in each disease. Our proposed integrated bioinformatics methodology is implemented in programming language R by incorporating several Bioconductor packages. Using the threshold p-value of 0.05 and absolute logFC value of 1, we identified discriminative sets of DEGs and GO terms which improve on current approaches to finding common DEGs and biological pathways among a group of diseases of interest. We have applied the process on microarray datasets for the selected pathologies that are publicly available and also suit our approach.
The proposed methodology is data-driven and it should be noted that the choice of the dataset would have qualitative and quantitative impacts on the results, and the use of a larger number of microarray datasets may enrich the evidence. We observe that taking into account data from different sources and cell types could strengthen the evidence obtained. Our proposed methodology used here for T2D and neurological comorbidities could be widely used, and it has two particular uses to uncover possible mechanisms of T2Dassociated activities that drive the development of neurological diseases, and as a means to identify possible significant comorbidities.
The development of bioinformatics methodology by utilizing omics and molecular data is providing new opportunities for medical practitioners to enhance clinical decision-making such as disease risk evaluation, disease diagnosis, and subtyping, drug therapy, and dose selection [120] and represent a step toward the development of truly personalized medicine. Thus, our methodology can provide fundamental new insights into disease mechanisms, and such identified disease mechanisms could be useful for further investigations to develop novel therapeutic targets.
V. CONCLUSION
In this study, we have considered transcriptomics, omics and molecular level data to investigate how the proposed methodology can be used to identify neurological disease comorbidities with T2D. We found that these neurological diseases are highly connected with T2D in terms of common biological processes, pathways and omics data as for example GO. Our findings indicate that the progression of complex diseases could be identified and studied using bioinformatics methodology as it offers the potential to enhance our understanding of complex human diseases. Identification of comorbidity interactions has a clinical interest because it may reveal new information about disease-causing factors as well as new therapeutic targets. This study demonstrates the worth of an integrated bioinformatics methodology in revealing possible disease relationships and opportunities for drug repositioning. Thus, we can say that this kind of approach will be helpful for making evidence-based recommendations about disease comorbidities. Our proposed approach could be extended as a comorbidity map by integrating other disease data besides neurological diseases. Our methodology is also likely to be useful not only for T2D research but also for the study of other complex diseases. Researchers and medical practitioners may use it as an important tool to uncover details of underlying disease mechanisms that underpin the biology and etiology of disease comorbidity and for the establishment of more effective and efficient treatments, perhaps within the context of an individualized and personalized pharmacotherapy. 
